Cargando…

Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy

INTRODUCTION: We designed a randomized, controlled prospective study aimed at comparing efficacy and tolerability of ezetimibe+fenofibrate treatment versus pravastatin monotherapy in dyslipidemic HIV-positive (HIV+) patients treated with protease inhibitors (PIs). METHODS: We consecutively enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grandi, Anna M, Nicolini, Eleonora, Rizzi, Laura, Caputo, Sara, Annoni, Filippo, Cremona, Anna M, Marchesi, Chiara, Guasti, Luigina, Maresca, Andrea M, Grossi, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4141938/ https://www.ncbi.nlm.nih.gov/pubmed/25148829 http://dx.doi.org/10.7448/IAS.17.1.19004

Ejemplares similares

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
por: Kumar, Shoba Sujana, et al.
Publicado: (2009)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia
por: Tano, Kanako, et al.
Publicado: (2019)

Liver Injury Associated With Ezetimibe Monotherapy
por: Kanagalingam, Tharsan, et al.
Publicado: (2020)

Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
por: Chilbert, Maya R, et al.
Publicado: (2022)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011)

Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase
por: van der Veen, Jelske N., et al.
Publicado: (2017)

Ternary Eutectic Ezetimibe–Simvastatin–Fenofibrate System and the Physical Stability of Its Amorphous Form
por: Knapik-Kowalczuk, Justyna, et al.
Publicado: (2021)

Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease
por: Tadiboyina, Venu T, et al.
Publicado: (2005)

Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2009)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study
por: Oikawa, Shinichi, et al.
Publicado: (2017)

Relationship between Dietary Habits and Control of Lipid Profiles in Patients with Dyslipidemia Using Pravastatin
por: Kang, Seo Young, et al.
Publicado: (2021)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

Rhabdomyolysis Associated with Fenofibrate Monotherapy in a Patient with Chronic Myelogenous Leukemia
por: Kato, Kazuya, et al.
Publicado: (2011)

The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes
por: Shinnakasu, Atsushi, et al.
Publicado: (2017)

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
por: Farnier, Michel
Publicado: (2008)

Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021
por: Katzmann, Julius L., et al.
Publicado: (2022)

In vitro effects of Apixaban on 5 different cancer cell lines
por: Guasti, Luigina, et al.
Publicado: (2017)

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy
por: Lee, Jun-beom, et al.
Publicado: (2017)

Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2021)

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia
por: Bays, Harold E., et al.
Publicado: (2010)

Comparative Efficacy and Safety of Statin Monotherapy and Statin plus Ezetimibe Combination in a Real-World Setting
por: Ezhov, Marat V., et al.
Publicado: (2023)

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010)

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
por: Tarantino, Nicola, et al.
Publicado: (2017)

The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
por: Yoon, Hye Eun, et al.
Publicado: (2009)

Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients
por: Abramson, Beth L, et al.
Publicado: (2011)

Pravastatin for prevention of HELLP syndrome: A case report
por: Otten, Lucia Anna, et al.
Publicado: (2017)

Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial
por: Xu, Jin, et al.
Publicado: (2023)

Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis
por: Salna, Michael P., et al.
Publicado: (2017)

Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review
por: Wang, Dawei, et al.
Publicado: (2018)

Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia
por: Machado-Duque, Manuel E., et al.
Publicado: (2020)

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
por: Foody, JoAnne M, et al.
Publicado: (2013)

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients
por: Saeedi, Ramesh, et al.
Publicado: (2015)

Effect of Ezetimibe Monotherapy on Low-Density Lipoprotein Cholesterol and on Markers of Cholesterol Synthesis and Absorption in Japanese Patients With Hypercholesterolemia
por: Ohta, Akio, et al.
Publicado: (2017)

Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2020)

Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review
por: Chauhan, Dhruva, et al.
Publicado: (2022)

Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
por: Teramoto, Tamio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_83ehn43gutr02shllsu0jpbbvu